

DAFTAR PUSTAKA

1. Lode wahyuni, Nacak NAS. Gambaran Penggunaan Kombinasi Obat Sintetis Dan Obat Tradisional Pada Pasien Rawat Jalan Di Instalasi Farmasi Upt Rsud Nene Mallomo Kabupaten Sidenreng Rappang Tahun 2024. *Jurnal Farmasi Al-Ghafiqi (JUFAL)*. 2024;20(20).
2. Abdullah M, Abd Halim AN, Jong VY, Sulainan SN, Zamakshshari NH. Rubraxanthone: A Promising Xanthone From Guttiferae Family with Diverse Biological Activities. *Chem Biodivers*. 2025 Sep 26;22(9).
3. Lee HH, Chan HK. 1,3,6-Trihydroxy-7-methoxy-8-(3,7-dimethyl-2,6-octadienyl) xanthone from *Garcinia cowa*. *Phytochemistry*. 1977 Jan;16(12):2038–40.
4. Dachriyanus, Dianita R, Jubahar J. Isolasi senyawa antioksidan dari kulit batang *Garcinia cowa* Roxb. *Jurnal Matematika dan Pengetahuan Alam*. 2003;12(2):67–72.
5. Sri Wahyuni F, Shaari K, Stanslas J, Hj Lajis N. Cytotoxic xanthenes from the stem bark of *Garcinia cowa* Roxb. Available online www.jocpr.com *Journal of Chemical and Pharmaceutical Research*. 2015;7(1):227–36.
6. Dachriyanus, Sartika L, Kesuma M, Mukhtar. Efek Senyawa Rubraxanthon Terhadap Kadar Kolesterol Total, Trigliserida, HDL dan LDL Dalam Darah Mencit Putih Jantan. *Jurnal Sains dan Teknologi Farmasi*. 2006;11(1):12–5.
7. Wahyuni FS, Israf Ali DA, Lajis NHj, DD. Anti-inflammatory activity of isolated compounds from the stem bark of *Garcinia cowa* Roxb. *Pharmacognosy Journal*. 2016 Nov 20;9(1):55–7.
8. Jantan I, Pizar MMD, Idris MS, Taher M, Ali RM. In Vitro Inhibitory Effect of Rubraxanthone Isolated from *Garcinia parvifolia* on Platelet-Activating Factor Receptor Binding. *Planta Med*. 2002 Dec;68(12):1133–4.
9. Alen Y, Safitri N, Manaf Ali A, Ladjis NH, V Sargent dan M. Rubraxanthone Dari *Garcinia Forbesii* King. dan Bioaktivitasnya. *J. Ris. Kim*. 2008.
10. Alkadi Khaled, Adam A, Taha M, Hasan M, Shah S. Prenylated Xanthone and Rubraxanthone with Antiplatelet Aggregation Activity in Human Whole Blood Isolated from *Garcinia griffithii*. *Oriental Journal of Chemistry*. 2013 Dec 30;29(4):1291–5.
11. Na Pattalung P, Wiriyachitra P, Ongsakul M. The Antimicrobial Activities Of Rubraxanthone Isolated From *Garcinia Parvifolia* (Miq.) Miq. *ScienceAsia*. 1988;14(1):067.

12. Ee GC, Foo C, Jong V, Ismail NH, Sukari MA, Yap YH, et al. A new xanthone from *Garcinia nitida*. *Nat Prod Res*. 2012 May;26(9):830–5.
13. Kurniawan RN, Ersam T. Isolasi Senyawa Rubrasanton dan Parvifolisanton C dari Ekstrak Kulit Batang *Garcinia Tetrandra* Pierre. *Jurnal Sains dan Seni ITS*. 2018 Mar 29;7(1).
14. Darwati D, Nurlelasari N, Mayanti T. Senyawa Steroid Dari Akar Tumbuhan Asam Kandis (*Garcinia Cowa*) Sebagai Obat Penurun Demam. *Jurnal Penelitian Hasil Hutan*. 2019 Apr 15;37(1):51–7.
15. Rasyid R, Armin F, Andayani R, Rivai H. Determination of Total Phenolic Content and Antioxidant Activities from Extract of the Leaf, Fruit Skin and Stem Bark of *Garcinia cowa* Roxb. *Int Journal of Pharmaceutical Sciences and Medicine (IJPSM)*. 2018;3:1–7.
16. Prayogo FA, Adinatha NN, Sari MO. *Farmakologi Dasar untuk Mahasiswa Ilmu Biomedis*. Bekasi: PT Penerbit Naga Pustaka; 2025.
17. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome p450 enzymes and drug metabolism in humans. *Int J Mol Sci*. 2021 Dec 1;22(23).
18. Shargel Leon, Yu ABC. *Applied biopharmaceutics & pharmacokinetics*. 7th ed. New York: McGraw-Hill Education; 2016.
19. Zuo HL, Huang HY, Lin YCD, Cai XX, Kong XJ, Luo DL, et al. Enzyme Activity of Natural Products on Cytochrome P450. *Molecules*. 2022 Jan 14;27(2):515.
20. Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC. In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract. *Drug Metabolism and Disposition*. 2009;37(9):1848–55.
21. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's Wort (*Hypericum perforatum*) on Tacrolimus Pharmacokinetics in Healthy Volunteers. *J Clin Pharmacol*. 2004 Jan;44(1):89–94.
22. Saxena A, Parijat Tripathi K, Roy S, Khan F, Sharma A. Current Trends Pharmacovigilance: Effects of herbal components on human drugs interactions involving Cytochrome P450. *print) Bioinformation*. 2008.
23. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. *British Journal of Pharmacology*. 2007. p. 9–20.
24. Moradi M, Golmohammadi R, Najafi A, Moosazadeh Moghaddam M, Fasihi-Ramandi M, Mirnejad R. A contemporary review on the important

- role of in silico approaches for managing different aspects of COVID-19 crisis. *Informatics in Medicine Unlocked*. Elsevier Ltd; 2022.
25. Sharma A, Kunwar S, Vaishali, Agarwal V, Singh C, Sharma Md, Et Al. Molecular Docking: An Explanatory Approach In Structure-Based Drug Designing And Discovery. *Int J Pharm Pharm Sci*. 2021 Jun 1;6–12.
 26. Wang X, Song K, Li L, Chen L. Structure-Based Drug Design Strategies and Challenges. *Curr Top Med Chem*. 2018 Sep 18;18(12):998–1006.
 27. Ajjarapu SM, Tiwari A, Ramteke PW, Singh DB, Kumar S. Ligand-based drug designing. In: *Bioinformatics*. Elsevier; 2022. p. 233–52.
 28. Issa NT, Byers SW, Dakshanamurthy S. ES-Screen: A Novel Electrostatics-Driven Method for Drug Discovery Virtual Screening. *Int J Mol Sci*. 2022 Nov 27;23(23):14830.
 29. Li Z, Huang R, Xia M, Patterson TA, Hong H. Fingerprinting Interactions between Proteins and Ligands for Facilitating Machine Learning in Drug Discovery. *Biomolecules*. 2024 Jan 5;14(1):72.
 30. Zhang X, Shen C, Wang T, Deng Y, Kang Y, Li D, et al. ML-PLIC: a web platform for characterizing protein–ligand interactions and developing machine learning-based scoring functions. *Brief Bioinform*. 2023 Sep 20;24(5).
 31. Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key Topics in Molecular Docking for Drug Design. *Int J Mol Sci*. 2019 Sep 15;20(18):4574.
 32. Sindt F, Seyller A, Eguida M, Rognan D. Protein Structure-Based Organic Chemistry-Driven Ligand Design from Ultralarge Chemical Spaces. *ACS Cent Sci*. 2024 Mar 27;10(3):615–27.
 33. Salmaso V, Moro S. Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview. *Front Pharmacol*. 2018 Aug 22;9.
 34. Gioia D, Bertazzo M, Recanatini M, Masetti M, Cavalli A. Dynamic Docking: A Paradigm Shift in Computational Drug Discovery. *Molecules*. 2017 Nov 22;22(11):2029.
 35. A T, VA B. Molecular Docking: From Lock and Key to Combination Lock. *J Mol Med Clin Appl*. 2018;2(1).
 36. Mohanty M, Mohanty PS. Molecular docking in organic, inorganic, and hybrid systems: a tutorial review. *Monatshefte fur Chemie*. Springer; 2023. p. 683–707.

37. Meng XY, Zhang HX, Mezei M, Cui M. Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. *Current Computer Aided-Drug Design*. 2011 Jun 1;7(2):146–57.
38. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem*. 2010 Jan 30;31(2):455–61.
39. Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein–ligand docking and virtual drug screening with the AutoDock suite. *Nat Protoc*. 2016 May 14;11(5):905–19.
40. Ravindranath PA, Forli S, Goodsell DS, Olson AJ, Sanner MF. AutoDockFR: Advances in Protein-Ligand Docking with Explicitly Specified Binding Site Flexibility. *PLoS Comput Biol*. 2015;11(12).
41. The Scripps Research Institute. MGLTools (Molecular Graphics Laboratory Tools) [Internet]. 2023 [dikunjungi 2025 Nov 8]. Available from: <https://ccsb.scripps.edu/mgltools/>
42. Anggraeni VJ, Purwaniati P, Budiana W, Nurdin T. Molecular Docking Compounds In Methanol Extract Of Mango Leaves (*Mangifera Indica L.*) As Anti-Inflammatory Agent. *Jurnal Kimia Riset*. 2022 Jun 30;7(1):57–65.
43. An overview on Windows Terminal Microsoft Learn [Internet]. [dikunjungi 2025 Nov 9]. Available from: <https://learn.microsoft.com/en-us/windows/terminal/>
44. Pontana Putra P. Docking Tutorial Using Autodock Vina Old Version 2010. 2021.
45. Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. SOFTWARE Open Access Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *Journal of Cheminformatics*. 2012.
46. David L, Thakkar A, Mercado R, Engkvist O. Molecular representations in AI-driven drug discovery: a review and practical guide. *Journal of Cheminformatics*. BioMed Central Ltd; 2020.
47. Baroroh, S.Si., M.Biotek. U, Muscifa ZS, Destiarani W, Rohmatullah FG, Yusuf M. Molecular interaction analysis and visualization of protein-ligand docking using Biovia Discovery Studio Visualizer. *Indonesian Journal of Computational Biology (IJCB)*. 2023 Jul 21;2(1):22.
48. Saudale FZ, Lerrick RI, Parikesit AA, Mariti F. Chemistry teachers' awareness, understanding, and confidence toward computational tools for

- molecular visualization. *Jurnal Pendidikan IPA Indonesia*. 2019 Dec 1;8(4):436–46.
49. Iinuma M, Tosa H, Tanaka T, Riswan S. Three New Xanthonenes from the Bark of *Garcinia dioica*. *Chem Pharm Bull (Tokyo)*. 1996;44(1):232–4.
 50. Wahyuni FS, Shaari K, Stanslas J, Lajis NH, Hamidi D. Cytotoxic properties and complete nuclear magnetic resonance assignment of isolated xanthonenes from the root of *Garcinia cowa* Roxb. *Pharmacogn Mag*. 2016;12(45):S52–6.
 51. Dachriyanus, Asjar NS, Susanti M. Determination of rubraxanthone in the latex of asam kandis (*Garcinia cowa* Roxb) by reverse phase high performance liquid chromatography. *Pharmacognosy Journal*. 2017;9(2):288–91.
 52. Wahyuni FS, Byrne LT, Dachriyanus, Dianita R, Jubahar J, Lajis NH, et al. A New Ring-Reduced Tetraprenyltoluquinone and a Prenylated Xanthone from *Garcinia cowa*. *Aust J Chem*. 2004 Mar 1;57(3):223–6.
 53. Susanti M, Darmianti R, Harahap Y, Itam A, Hamidi D. Single dose oral pharmacokinetic profile rubraxanthone in mice. *Heliyon*. 2022 Mar 1;8(3).
 54. Cham C. The Role of Cytochrome P450 Enzymes in Hepatic Drug Metabolism and Pharmacokinetics. *World Journal of Pharmacology and Toxicology*. 2025.
 55. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. *Front Pharmacol*. 2010;1.
 56. Benowitz N, Swan G, Jacobiii P, Lessovschlaggar C, Tyndale R. Cyp2a6 genotype and the metabolism and disposition kinetics of nicotine. *Clin Pharmacol Ther*. 2006 Nov;80(5):457–67.
 57. Vizeli P, Schmid Y, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. *European Neuropsychopharmacology*. 2017 Mar;27(3):232–8.
 58. Daily EB, Aquilante CL. Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical Studies. *Pharmacogenomics*. 2009 Sep 17;10(9):1489–510.
 59. Yenilmez ED, Tamam L, Karaytug O, Tuli A. Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine. *Comb Chem High Throughput Screen*. 2018 Jul 20;21(5):374–80.

60. de Andrés F, Altamirano-Tinoco C, Ramírez-Roa R, Montes-Mondragón CF, Dorado P, Peñas-Lledó EM, et al. Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population. *Pharmacogenomics J.* 2021 Apr 6;21(2):140–51.
61. Lieber CS. Cytochrome P-450E1: its physiological and pathological role. *Physiol Rev.* 1997 Apr 1;77(2):517–44.
62. Zhou SF. Drugs Behave as Substrates, Inhibitors and Inducers of Human Cytochrome P450 3A4. *Curr Drug Metab.* 2008 May 1;9(4):310–22.
63. Chen J, Tang LWT, Jordan S, Harrison M, Gualtieri GM, DaSilva E, et al. Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates. *AAPS J.* 2024 Feb 16;26(2):26.
64. Wei Y, Palazzolo L, Ben Mariem O, Bianchi D, Laurenzi T, Guerrini U, et al. Investigation of in silico studies for cytochrome P450 isoforms specificity. *Computational and Structural Biotechnology Journal.* Elsevier B.V.; 2024. p. 3090–103.
65. Zhong HA. ADMET Properties: Overview and Current Topics. In: *Drug Design: Principles and Applications.* Singapore: Springer Singapore; 2017. p. 113–33.
66. Doehmer J, Weiss G, McGregor GP, Appel K. Assessment of a dry extract from milk thistle (*Silybum marianum*) for interference with human liver cytochrome-P450 activities. *Toxicology in Vitro.* 2011 Feb;25(1):21–7.
67. Li J, Gödecke T, Chen SN, Imai A, Lankin DC, Farnsworth NR, et al. In vitro metabolic interactions between black cohosh (*Cimicifuga racemosa*) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. *Xenobiotica.* 2011 Dec 9;41(12):1021–30.
68. Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, et al. Influence of Panax ginseng on Cytochrome P450 CYP3A and P-glycoprotein (P-gp) Activity in Healthy Participants. *The Journal of Clinical Pharmacology.* 2012 Jun 7;52(6):932–9.
69. Kim Y, Jo JJ, Cho P, Shrestha R, Kim KM, Ki SH, et al. Characterization of red ginseng interaction by CYP3A activity increased in high dose administration in mice. *Biopharm Drug Dispos.* 2020 Jul 17;41(7):295–306.
70. Sherifdeen MM, Alehaideb ZI, Law FCP. Caffeine/Angelica dahurica and caffeine/Salvia miltiorrhiza metabolic inhibition in humans: In vitro and in vivo studies. *Complement Ther Med.* 2019 Oct;46:87–94.

71. Wanwimolruk S, Prachayasittikul V. Cytochrome P450 Enzyme Mediated Herbal Drug Interactions (Part 1). *Excli J.* 2014;13.
72. Wanwimolruk S, Phopin K, Prachayasittikul V. Cytochrome P450 Enzyme Mediated Herbal Drug Interactions (Part 2). *Excli Journal.* 2014.
73. putra PP. Teori dan Tutorial Molecular Docking Menggunakan AutoDock Vina . Jawa Tengah: Wawasan Ilmu; 2022.
74. Rena SR, Nurhidayah N, Rustan R. Analisis Molecular Docking Senyawa *Garcinia Mangostana L* Sebagai Kandidat Anti SARS-CoV-2. *Jurnal Fisika Unand.* 2022 Feb 17;11(1):82–8.
75. Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. *J Comput Chem.* 2007 Apr 30;28(6):1145–52.
76. Ferreira L, Dos Santos R, Oliva G, Andricopulo A. Molecular Docking and Structure-Based Drug Design Strategies. *Molecules.* 2015 Jul 22;20(7):13384–421.
77. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nat Rev Drug Discov.* 2004 Nov 1;3(11):935–49.
78. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem.* 2009 Dec 27;30(16):2785–91.
79. Ramírez D, Caballero J. Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? *Molecules.* 2018 Apr 28;23(5):1038.
80. Leach AR. *Molecular modelling : principles and applications.* Prentice Hall; 2001. 744 p.
81. Copeland RA. *Evaluation of Enzyme Inhibitors in Drug Discovery.* Wiley; 2013.
82. DeVore NM, Scott EE. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. *Journal of Biological Chemistry.* 2012 Aug 3;287(32):26576–85.
83. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. *Nat Struct Mol Biol.* 2005 Sep;12(9):822–3.

84. Bissantz C, Kuhn B, Stahl M. A Medicinal Chemist's Guide to Molecular Interactions. *J Med Chem*. 2010 Jul 22;53(14):5061–84.
85. Kumar S, Nussinov R. Salt bridge stability in monomeric proteins 1 1 Edited by J. M. Thornton. *J Mol Biol*. 1999 Nov;293(5):1241–55.
86. Du X, Li Y, Xia YL, Ai SM, Liang J, Sang P, et al. Insights into Protein–Ligand Interactions: Mechanisms, Models, and Methods. *Int J Mol Sci*. 2016 Jan 26;17(2):144.
87. Wintjens R, Liévin J, Rooman M, Buisine E. Contribution of cation- π interactions to the stability of protein-DNA complexes 1 1 Edited by J. Thornton. *J Mol Biol*. 2000 Sep;302(2):393–408.
88. Wang Y, Sun K, Li J, Guan X, Zhang O, Bagni D, et al. A workflow to create a high-quality protein–ligand binding dataset for training, validation, and prediction tasks. *Digital Discovery*. 2025;4(5):1209–20.
89. Di YM, Chow VDW, Yang LP, Zhou SF. Structure, Function, Regulation and Polymorphism of Human Cytochrome P450 2A6. *Current Drug Metabolism*. 2009.

